Vineet Laboratories Limited has informed the Exchange regarding Board meeting held on May 12, 2025 for the following: approved the Audited Standalone Financial Results of the company for the fourth quarter and the financial year ended on 31st March 2025 and the Audited Standalone Financial Statement for the financial year ended on 31st March 2025 along with Audit Report. approved the re-appointment of Mr. Dilip Vishnu Acharekar (DIN: 08849689) as an independent director of the Company. recommended the appointment of M/s. P S Rao & Associates, Company Secretaries as the Secretarial Auditor of the Company for a period of 5 consecutive years for the approval of the shareholders at the ensuing Annual General Meeting.
VINEETLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vineet Laboratories' board met on May 12, 2025 and approved the audited standalone financial results for Q4 and FY ended March 31, 2025. Revenue from operations fell sharply to about ₹75 crore in FY25 from about ₹150.8 crore in FY24, a drop of roughly 50% year-on-year. The company swung from a small profit of about ₹1 crore in FY24 to a loss of about ₹20.2 crore in FY25, with EPS turning negative at ₹(21.90). The statutory auditor (NSVR & Associates LLP) issued an unqualified opinion but flagged an Emphasis of Matter noting that ₹7.12 crore of slow-moving and obsolete inventory was written off and charged to the P&L. The board also re-appointed Mr. Dilip Vishnu Acharekar as Independent Director for a second 5-year term (Nov 2025 to Nov 2030) and proposed appointing M/s. P S Rao & Associates as Secretarial Auditor for 5 years (FY26 to FY30), subject to shareholder approval.
This is a significantly negative result for shareholders — the company has reported a steep revenue decline and its first major annual loss, with auditor-flagged inventory write-offs suggesting demand or operational issues in the API/intermediates business. The stock is likely to react negatively on the back of these results.